Bentham Cardiovascular Disorders Collection | Cardiovascular Disorders | Aortic Coarctation
Background: Numerous studies indicate that statins have multiple beneficial actions (known as ‘pleiotropic actions’) on cardiovascular system through the improvement of endothelial dysfunction, inflammation, oxidative stress, excessive arterial thrombosis, and stabilization of the atherosclerotic plaque. Aortic disease primarily consists of aortic valve stenosis, aortic valve regurgitation, aneurysm disease, and genetic disorders such as Marfan syndrome, bicuspid aortic valve and aortic coarctation. Many studies have revealed the cardioprotective actions of statins in aortic disease.
Objective: Our aim was to present current data concerning the value of treatment with statins in aortic diseases.
Methods: A thorough search of PubMed and the Cochrane Database was conducted to identify the studies and novel articles related to the use of statins in aortic disease.
Results: Numerous studies in animals and humans indicate a beneficial effect of treatment with statins in the previous conditions apart from a few conflicting data.
Conclusion: There is a need of further investigation in this field, especially for the estimation of the optimal type and dose of statins required in each clinical condition of aortic disease.
Journal: Current Pharmacogenomics and Personalized Medicine
Author(s): Valentina Manzo, Sara Tarallo, Teresa Iannaccone, Maria Costantino, Walter Filippelli, Amelia Filippelli.
Background: Variability in response to pharmacological treatment is one of the most important issues in the clinical practice at first exclusively attributed to clinical and demographic factors such as age, sex, nutritional status, alcohol abuse, smoking, presence of comorbidities and polypharmacy. Nowadays, it is well known that also genetic factors can modify the outcomes of pharmacological treatments. Polymorphisms in genes encoding molecules involved in both pharmacodynamics and pharmacokinetics may influence efficacy, tolerability, and safety of medications; thus, the knowledge of these genetic variants may help physicians to individualize and optimize the therapies.
Objective: The main aim of this review is to summarize the current scientific evidence about cardiovascular pharmacogenomics.
Conclusion: Cardiovascular pharmacogenomics is recommended only for some antiplatelet, anticoagulant and antihypercholesterolemic drugs thanks to standardized pharmacogenetic tests that are helpful in preventing thromboembolic and hemorrhagic events. Despite many studies have demonstrated that the application of pharmacogenetics may be useful also to individualize the therapy with other cardiovascular drugs, the paucity of large clinical trials and of cost-effectiveness studies limits the translation of such knowledge into clinical practice.